CRL — Charles River Laboratories stock price and chart

CRL

Charles River LaboratoriesStock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.02% · Russell 3000 0.02% · Russell 1000 0.02% · US Stock Market 0.02%

$278.06-1.28%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

100.0150.0200.0250.0300.0350.0400.0010.0M20.0M$278.06

2026-09-18

Price$278.06

MA20$221.11

MA50$194.13

Vol4.3M

What would $1,000 invested in CRL be worth today? →

CRL returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $278.06
Change YTD: +39.39%
Next earnings: Nov 4, 2026
Market cap: 13.3B2016-09 3.9B2026-09 13.3B+236.5% over the window
Enterprise value: 16.2B
Shares outstanding: 47.7M2016-06 47.3M2026-06 47.7M+0.9% over the window
52W low: $144.26
52W high: $303.31
From 52W high: -8.32%
From 52W low: +92.75%
52W range: 84%
Beta: 1.37

Volume

Rel volume: 1.63×
30D volume: 908.5K
30D $ vol: 258.1M

Fundamentals

Sales (ttm): 4B2016-06 1.5B2026-06 4B+168.0% over the window
Sales/share: $83.772016-06 $31.552026-06 $83.77+165.5% over the window
EPS (ttm): -$4.892016-06 $2.972026-06 -$4.89-264.6% over the window
FCF (ttm): 370.6M2016-06 276.4M2026-06 370.6M+34.1% over the window
FCF/share: $7.762016-06 $5.852026-06 $7.76+32.8% over the window
Book value/share: $59.482016-06 $17.582026-06 $59.48+238.4% over the window
Net margin: -5.96%2016-06 9.5%2026-06 -6.0%-162.8% over the window
ROE: -8.40%2016-06 17.0%2026-06 -8.4%-149.3% over the window
ROA: -3.17%2016-06 5.1%2026-06 -3.2%-161.8% over the window
Debt / equity: 0.92×2016-06 1.582026-06 0.92-41.5% over the window
Current ratio: 1.352016-06 1.702026-06 1.35-20.6% over the window

Growth (CAGR, ttm) · 10Y

Sales: -0.74%2025-06-28 → 2026-06-274B → 4B (-0.7% total)-1.46%2023-07-01 → 2026-06-274.2B → 4B (-4.3% total)+4.08%2021-06-26 → 2026-06-273.3B → 4B (+22.2% total)+10.36%2016-06-25 → 2026-06-271.5B → 4B (+168.0% total)
FCF: -36.03%2025-06-28 → 2026-06-27578.5M → 370.6M (-35.9% total)+8.63%2023-07-01 → 2026-06-27289.4M → 370.6M (+28.1% total)-5.20%2021-06-26 → 2026-06-27484M → 370.6M (-23.4% total)+2.97%2016-06-25 → 2026-06-27276.4M → 370.6M (+34.1% total)
Shares: -3.01%2025-06-28 → 2026-06-2749.2M → 47.7M (-3.0% total)-2.36%2023-07-01 → 2026-06-2751.3M → 47.7M (-6.9% total)-1.08%2021-06-26 → 2026-06-2750.4M → 47.7M (-5.3% total)+0.09%2016-06-25 → 2026-06-2747.3M → 47.7M (+0.9% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +2.34%2025-06-28 → 2026-06-27$81.86 → $83.77 (+2.3% total)+0.92%2023-07-01 → 2026-06-27$81.49 → $83.77 (+2.8% total)+5.22%2021-06-26 → 2026-06-27$64.95 → $83.77 (+29.0% total)+10.25%2016-06-25 → 2026-06-27$31.55 → $83.77 (+165.5% total)
FCF/share: -34.05%2025-06-28 → 2026-06-27$11.75 → $7.76 (-34.0% total)+11.25%2023-07-01 → 2026-06-27$5.64 → $7.76 (+37.6% total)-4.16%2021-06-26 → 2026-06-27$9.60 → $7.76 (-19.2% total)+2.88%2016-06-25 → 2026-06-27$5.85 → $7.76 (+32.8% total)
Book value/share: -12.74%2025-06-28 → 2026-06-27$68.14 → $59.48 (-12.7% total)-2.12%2023-07-01 → 2026-06-27$63.42 → $59.48 (-6.2% total)+5.27%2021-06-26 → 2026-06-27$46.00 → $59.48 (+29.3% total)+12.96%2016-06-25 → 2026-06-27$17.58 → $59.48 (+238.4% total)
Price: +77.19%2025-09-18 → 2026-09-18$156.99 → $278.06 (+77.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+9.71%2023-09-18 → 2026-09-18$210.57 → $278.06 (+32.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-8.79%2021-09-17 → 2026-09-18$440.45 → $278.06 (-36.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+13.12%2016-09-16 → 2026-09-18$81.02 → $278.06 (+243.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +77.19%2025-09-18 → 2026-09-18$156.99 → $278.06 (+77.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+9.71%2023-09-18 → 2026-09-18$210.57 → $278.06 (+32.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-8.79%2021-09-17 → 2026-09-18$440.45 → $278.06 (-36.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.12%2016-09-16 → 2026-09-18$81.02 → $278.06 (+243.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -56.9×2016-09 27.782026-09 -55.67-300.4% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 147.3×2016-09 17.882026-09 147.26+723.6% over the window
Fwd P/E: 21.6×
P/S (ttm)Market cap ÷ TTM revenue.: 3.3×2016-09 2.512026-09 3.32+32.0% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.7×2016-09 4.542026-09 4.67+2.9% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 35.8×2016-09 15.092026-09 35.82+137.3% over the window
EV/EBITDA (fy): 41.8×
EV/Sales (ttm): 4.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.79%2016-06 7.0%2026-06 3.5%-50.4% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-27) ÷ shares_at(2025-06-28) = 1 − 47.7M ÷ 49.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.01%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.01%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-28) ($7.4B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.01%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($324.1M) ÷ today's market cap ($13.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.44%2016-06 0.8%2026-06 3.0%+296.8% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $324.1M + TTM dividends $0) ÷ today's market cap ($13.3B). Same caveat as the cash buyback yield.: 2.44%2016-06 0.8%2026-06 3.0%+296.8% over the window

Vs own 10Y history

P/E: 97th
P/OI: 97th
P/S: 80th
P/B: 58th
P/FCF: 83rd

Bar = where today’s multiple sits in CRL’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-1.28%

-0.07%

-0.40%

+50.30%

YTD

+39.39%

+77.12%

-36.87%

Financial statements

Open full CRL financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-5.94%	+0.04%
JNJ	Johnson & Johnson	-0.41%	-0.09%
ABBV	AbbVie Inc.	+1.95%	-0.02%
MRK	Merck & Co. Inc.	+8.66%	-0.19%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-4.32%	+0.45%
TMO	Thermo Fisher Scientific Inc.	+10.60%	-1.04%
AMGN	Amgen Inc.	-9.32%	+1.55%
GILD	Gilead Sciences Inc.	+4.65%	-0.52%

Charles River Laboratories (CRL) trades at $278.06 with a live price and an interactive chart covering 26+ years of daily price history, plus key valuation metrics. ChartRow also publishes CRL’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full CRL financial statements →

CRL — Charles River Laboratories price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · as of 2026-09-18

Financial statements

Related Healthcare